News | December 20, 2011

Medical Centers Worldwide Adopting Accuray’s CyberKnife, TomoTherapy Systems

December 20, 2011 — Accuray announced that 23 leading medical centers globally have installed both a CyberKnife Robotic Radiosurgery System  and a TomoTherapy System. Combining the two systems will enable the delivery of personalized treatment for the full spectrum of radiation oncology patients.

These centers include smaller community sites in rural areas, mid-sized regional hospitals and large academic centers, indicating that centers of all sizes can benefit from these devices.

"We now have the ability to design treatments that fit the individual needs of all patients," said Sandra Vermuelen, M.D., executive medical director of the Swedish Radiosurgery Center in Seattle. "The CyberKnife and TomoTherapy systems are designed to allow clinicians to create specialized treatments with the ability to facilitate a complete range of treatment techniques ranging from static 3-D conformal and highly modulated intensity-modulated radiotherapy (IMRT), to stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). Through the use of daily image-guidance, a standard feature for TomoTherapy, and the CyberKnife system's ability to track, detect and automatically correct for tumor and patient movement, we can ensure the most accurate treatment delivery for all patients."

More than half the centers with both systems are in North America including St. John Medical Center in Tulsa, Centre Hospitalier de l'Universite in Montreal (CHUM) and Swedish Medical Center in Seattle. Recent centers in other nations that now have both systems installed and treating patients include Tokyo's Metropolitan Center and Infectious Diseases Center Komagome Hospital and Italy's Istituto Europeo di Oncologia.

For more information: www.accuray.com

 

 

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...